
Quarterly report 2025-Q3
added 11-04-2025
Corcept Therapeutics Incorporated Net Debt 2011-2026 | CORT
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Corcept Therapeutics Incorporated
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -121 M | - | - | - | - | -27.8 M | -41.6 M | -31.1 M | -36.9 M | -25.5 M | -14.8 M | -49.1 M | -90.4 M | -39.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -14.8 M | -121 M | -47.8 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
94.7 M | $ 18.38 | -0.68 % | $ 2.7 B | ||
|
Amgen
AMGN
|
44.7 B | $ 344.65 | 0.81 % | $ 185 B | ||
|
Arrowhead Pharmaceuticals
ARWR
|
-115 M | $ 71.99 | 3.84 % | $ 9.63 B | ||
|
Biogen
BIIB
|
4.01 B | $ 178.18 | -0.95 % | $ 25.9 B | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
Aytu BioScience
AYTU
|
-19.9 M | $ 2.65 | 1.92 % | $ 16.6 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Adagene
ADAG
|
-71 M | $ 2.96 | 7.64 % | $ 167 M | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Burford Capital Limited
BUR
|
-135 M | $ 9.83 | 1.44 % | $ 1.59 B | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 4.16 | 3.74 % | $ 9.05 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 3.18 | 0.32 % | $ 7.65 B | ||
|
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | ||
|
Compugen Ltd.
CGEN
|
-5.05 M | $ 1.86 | 1.1 % | $ 167 M | ||
|
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | ||
|
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | ||
|
Celldex Therapeutics
CLDX
|
-24.5 M | $ 24.86 | 1.06 % | $ 1.6 M | ||
|
Cellectis S.A.
CLLS
|
-206 M | $ 3.87 | 2.22 % | $ 116 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
-21.3 M | $ 1.41 | - | $ 264 M | ||
|
Albireo Pharma
ALBO
|
-239 M | - | -0.23 % | $ 916 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Allena Pharmaceuticals
ALNA
|
-29.5 M | - | 3.16 % | $ 1.9 M | ||
|
Ascendis Pharma A/S
ASND
|
-195 M | $ 224.87 | -0.54 % | $ 5 B | ||
|
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | ||
|
Aravive
ARAV
|
-49.6 M | - | -13.39 % | $ 1.45 M | ||
|
BioNTech SE
BNTX
|
-973 M | $ 110.01 | -3.29 % | $ 27.2 B | ||
|
Athira Pharma
ATHA
|
-47.2 M | - | - | $ 269 M | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
Autolus Therapeutics plc
AUTL
|
-187 M | $ 1.39 | 1.5 % | $ 355 M | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
AVROBIO
AVRO
|
-76.6 M | - | 1083.1 % | $ 745 M | ||
|
Cardiff Oncology
CRDF
|
-49.9 M | $ 1.73 | -1.43 % | $ 82.4 M | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-119 M | - | -15.15 % | $ 60.3 M | ||
|
DBV Technologies S.A.
DBVT
|
-25.5 M | $ 21.75 | 0.65 % | $ 2.11 B | ||
|
Brickell Biotech
BBI
|
-29.7 M | - | -5.38 % | $ 6.06 M | ||
|
Amneal Pharmaceuticals
AMRX
|
2.28 B | $ 14.25 | 4.13 % | $ 4.4 B | ||
|
AIkido Pharma
AIKI
|
-1.04 M | - | 1.93 % | $ 17.4 M | ||
|
Atreca
BCEL
|
33.1 M | - | -11.76 % | $ 5.79 M | ||
|
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | ||
|
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | ||
|
BioCryst Pharmaceuticals
BCRX
|
211 M | $ 6.72 | 2.05 % | $ 1.39 B |